Related Experiment Video
Updated: Jul 2, 2025

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Case report: Gastric carcinoma with SMARCA4 deficient: two cases report and literature review
Zeyang Lin1, Qian Li1, Yujie He2
1Department of Pathology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Abstract:
SMARCA4-deficient gastric carcinoma has been reported sporadically since 2016. Only 29 patients have been reported; nevertheless, it is aggressive and highly malignant with poor outcomes. It has an immunohistochemical phenotype showing loss of SMARCA4 expression and can be accompanied by codeletion of other switch/sucrose non-fermentable chromatin-remodeling complex subunits. Microscopically, it displays high-grade undifferentiated histological morphology with rhabdoid cell differentiation. Rarely does the tumor contain a purely or partly adenocarcinoma component. Here, we report two cases to demonstrate these unusual morphologies analyzed using morphological and immunohistochemical techniques. In addition, there is a lack of research on the classification of these morphologies. Therefore, our report will aid the diagnosis and classification of SMARCA4-deficient gastric carcinoma.
Insights
SMARCA4-deficient gastric carcinoma is a rare and aggressive cancer. This report details two unusual cases, aiding in the diagnosis and classification of this malignant tumor.
Area of Science:
- Oncology
- Gastroenterology
- Pathology
Background:
- SMARCA4-deficient gastric carcinoma (SDGC) is a rare malignancy.
- Reported sporadically since 2016, with only 29 cases documented.
- SDGC is characterized by aggressive behavior and poor patient outcomes.

